Ryan Edward Brown sold $6.3M of SRPT
EVP, General Counsel at Sarepta Therapeutics, Inc.. 38,957 shares at an average of $161.61, traded Jun 25, 2024, filed Jun 25, 2024.
Score components
- +15RoleOfficer
- +25Trade size$6.3M at market
- +20Share of holdings soldSold 69% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-077522, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 21, 2024 | MOption exercise Common Stock10b5-1 | +6,250 | - | - | 34,938 | Jun 25, 2024 |
| Jun 24, 2024 | FTax withholding Common Stock10b5-1 | -2,352 | $164.64 | $387k | 32,586 | Jun 25, 2024 |
| Jun 25, 2024 | MOption exercise Common Stock10b5-1 | +23,500 | $62.77 | $1.5M | 56,086 | Jun 25, 2024 |
| Jun 25, 2024 | SOpen-market sale Common Stock10b5-1 | -7,644 | $158.07 | $1.2M | 48,442 | Jun 25, 2024 |
| Jun 25, 2024 | SOpen-market sale Common Stock10b5-1 | -2,200 | $159.14 | $350k | 46,242 | Jun 25, 2024 |
| Jun 25, 2024 | SOpen-market sale Common Stock10b5-1 | -975 | $160.31 | $156k | 45,267 | Jun 25, 2024 |
| Jun 25, 2024 | SOpen-market sale Common Stock10b5-1 | -4,168 | $161.82 | $674k | 41,099 | Jun 25, 2024 |
| Jun 25, 2024 | SOpen-market sale Common Stock10b5-1 | -17,581 | $162.65 | $2.9M | 23,518 | Jun 25, 2024 |
| Jun 25, 2024 | SOpen-market sale Common Stock10b5-1 | -3,840 | $163.53 | $628k | 19,678 | Jun 25, 2024 |
| Jun 25, 2024 | SOpen-market sale Common Stock10b5-1 | -2,549 | $164.52 | $419k | 17,129 | Jun 25, 2024 |
| Jun 21, 2024 | AGrant or award Performance Stock Unitsderivative10b5-1 | +5,500 | $0.00 | $0 | 5,500 | Jun 25, 2024 |
| Jun 21, 2024 | AGrant or award Performance Stock Unitsderivative10b5-1 | +6,250 | $0.00 | $0 | 6,250 | Jun 25, 2024 |
| Jun 21, 2024 | MOption exercise Performance Stock Unitsderivative10b5-1 | -6,250 | $0.00 | $0 | 0 | Jun 25, 2024 |
| Jun 25, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -23,500 | $0.00 | $0 | 0 | Jun 25, 2024 |
Related signals
Other insiders at Sarepta Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | SRPTsell Sarepta Therapeutics, Inc. | Stephen Mayo director | $123k 7,239 shares | -80% | |
| 34Weak | SRPTsell Sarepta Therapeutics, Inc. | Ian Michael Estepan Chief Operating Officer | $294k 13,187 shares | -6% | |
| 43Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.3M 10,500 shares | -31% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $205k 1,636 shares | -22% | |
| 50Moderate | SRPTsell Sarepta Therapeutics, Inc. | Ian Michael Estepan Chief Financial Officer | $822k 5,985 shares | -15% | |
| 47Moderate | SRPTbuy Sarepta Therapeutics, Inc. | Michael Andrew Chambers director | $5.0M 37,038 shares | +15% | |
| 23Weak | Sarepta Therapeutics, Inc. | Bilal Arif Chief Tech Ops Officer | $1.9M 11,757 shares | -40% | |
| 18Weak | Sarepta Therapeutics, Inc. | Dallan Murray Chief Customer Officer | $509k 3,635 shares | -17% | |
| 40Moderate | Sarepta Therapeutics, Inc. | Kathryn Jean Boor director | $94k 761 shares | -9% | |
| 50Moderate | Sarepta Therapeutics, Inc. | Hans Lennart Rudolf Wigzell director | $1.8M 15,000 shares | -40% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.